MoonLake rebounds despite downgrades prompted by trial setback
Source: SeekingAlpha
2025-09-30 13:34:03 ET
More on MoonLake Immunotherapeutics
- MoonLake: From 'Best-In-Class' Hopes To Approvability Debate (Rating Downgrade)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Call (Transcript)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Presentation - Slideshow
- MoonLake plunges after mixed results from skin disease trial
- Goldman's 48 potential M&A candidates
Read the full article on Seeking Alpha
For further details see:
MoonLake rebounds despite downgrades prompted by trial setback
Oruka Therapeutics Inc.
NASDAQ: ORKA
ORKA Trading
8.11% G/L:
$40.99 Last:
109,248 Volume:
$41.30 Open:
ORKA Latest News
March 12, 2026 04:05:20 pm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ORKA Stock Data
$1,591,695,548
36,456,993
2.59%
56
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
